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Knockdown of Ki-67 by Dicer-Substrate Small Interfering
RNA Sensitizes Bladder Cancer Cells to Curcumin-
Induced Tumor Inhibition
Sivakamasundari Pichu, Swapna Krishnamoorthy, Andrei Shishkov, Bi Zhang, Peter McCue,
Biddanda C. Ponnappa*
Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University, Philadelphia, Pennsylvania, United States of America
Abstract
Transitional cell carcinoma (TCC) of the urinary bladder is the most common cancer of the urinary tract. Most of the TCC
cases are of the superficial type and are treated with transurethral resection (TUR). However, the recurrence rate is high and
the current treatments have the drawback of inducing strong systemic toxicity or cause painful cystitis. Therefore, it would
be of therapeutic value to develop novel concepts and identify novel drugs for the treatment of bladder cancer. Ki-67 is a
large nucleolar phosphoprotein whose expression is tightly linked to cell proliferation, and curcumin, a phytochemical
derived from the rhizome Curcuma longa, has been shown to possess powerful anticancer properties. In this study, we
evaluated the combined efficacy of curcumin and a siRNA against Ki-67 mRNA (Ki-67-7) in rat (AY-27) and human (T-24)
bladder cancer cells. The anticancer effects were assessed by the determination of cell viability, apoptosis and cell cycle
analysis. Ki-67-7 (10 nM) and curcumin (10 mM), when treated independently, were moderately effective. However, in their
combined presence, proliferation of bladder cancer cells was profoundly (.85%) inhibited; the rate of apoptosis in the
combined presence of curcumin and Ki-67-7 (36%) was greater than that due to Ki-67-7 (14%) or curcumin (13%) alone. A
similar synergy between curcumin and Ki-67-7 in inducing cell cycle arrest was also observed. Western blot analysis
suggested that pretreatment with Ki-67-7 sensitized bladder cancer cells to curcumin-mediated apoptosis and cell cycle
arrest by p53- and p21-independent mechanisms. These data suggest that a combination of anti-Ki-67 siRNA and curcumin
could be a viable treatment against the proliferation of bladder cancer cells.
Citation: Pichu S, Krishnamoorthy S, Shishkov A, Zhang B, McCue P, et al. (2012) Knockdown of Ki-67 by Dicer-Substrate Small Interfering RNA Sensitizes Bladder
Cancer Cells to Curcumin-Induced Tumor Inhibition. PLoS ONE 7(11): e48567. doi:10.1371/journal.pone.0048567
Editor: Bharat B. Aggarwal, The University of Texas M. D. Anderson Cancer Center, United States of America
Received August 23, 2012; Accepted September 28, 2012; Published November 12, 2012
Copyright:  2012 Pichu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was partly supported by National Institutes of Health grant AA016551. The funding agency had no role in study design, data collection, and
analysis, decision to publish, or preparation of the manuscript. No additional external funding received for this study.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: Biddanda.Ponnappa@jefferson.edu
Introduction
Bladder cancer is the most common urological cancer in
Southeast Asia and the second most frequent urological malig-
nancy in North America [1]. Transitional cell carcinoma (TCC)
accounts for greater than 90% of patients diagnosed with bladder
cancer [2]. Greater than 70% of the TCC tumors are superficial
tumors confined to bladder mucosa and lamina propia -Ta or T1
staged tumors and the remaining are of the invasive type. The
incidence of urinary bladder cancer has continuously increased
during the past two decades [3]. A preferred treatment for
superficial tumors is transurethral resection (TUR), but the risk of
recurrence (60–70%) due to the reattachment of released tumor
cells and death from the disease (10–30%) is high [4]. The primary
approach to prevent the recurrence of the tumor, after TUR, has
been intravesical instillation therapy (IVI) using chemotherapeutic
drugs [5,6] but the cytotoxic effects of the drugs are of concern.
Because of its higher efficacy, intravesical immunotherapy using
Bacillus Calmette Guerin (BCG) has become the treatment of choice
during the past three decades. However, induction of cystitis and
systemic toxicity are some of its serious side effects [2]. Despite the
aggressive therapies, patients with bladder cancer have a 5-year
survival rate of only about 50% [7]. Further, substantial numbers
of bladder cancer patients are resistant to conventional intravesical
therapy and therefore, it is necessary to develop newer and
preferably less toxic approaches to combat the disease.
One of the newer approaches to suppress tumor progression is
by using gene-specific drugs such as, antisense oligonucleotides
(AsODNs) or small interfering RNAs (siRNAs) against mRNAs of
tumor-specific proteins. Following the discovery of RNA interfer-
ence (RNAi) in a variety of species [8–10], there has been a
tremendous interest in harnessing the therapeutic potential of
siRNAs in the treatment of various diseases [11], including cancer
[12] and inflammatory diseases [13]. Ki-67 is a large nucleolar
phosphoprotein whose expression is tightly linked with the cell
cycle and it is strictly associated with cell proliferation [14]. It is a
DNA-binding protein with a primary role in maintaining higher
order structure for DNA during the process of mitosis. Detailed
cell cycle analysis revealed that the Ki-67 antigen is present in
nuclei of proliferating (G1-, S-, G2- phase and mitosis) but not in
the nuclei of quiescent or resting cells (G0- phase) [15]. This
suggests that Ki-67 inhibitors may have relative specificity for
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malignant cells. Yoa et al., [16] reported that among many of the
cancer-related genes tested, that of Ki-67 expression was one of
the highest in rat bladder tumors, reaching nearly 20-fold higher
levels compared to normal tissue. Thus, Ki-67 has been one of the
genes of interest to target, using AsODNs [17,18] or siRNAs
[19,20]. In more recent report, AsODN against Ki-67 was used in
Phase-I clinical trials for the treatment of human bladder cancer
[21]. Although, the efficacy of AsODNs demonstrate the proof of
the principle, it is known that siRNAs are at least an order of
magnitude more sensitive than AsODNs [22,23] and hence, much
lower amount of the drug need to be used for similar efficacy.
Further, it has been shown that the longer (27 bp) Dicer-substrate
siRNAs (DsiRNAs) are more sensitive than the standard 19-21 bp
siRNAs [24]. Thus, siRNAs/DsiRNAs provide a better tool than
AsDONs to target tumor-specific genes.
In addition to the antisense molecules, in recent years, drugs of
plant origin have also received much attention due to their
enormous potential in the prevention and treatment of cancer
[25]. Curcumin is a polyphenolic phytochemical derived from the
rhizome, Curcuma longa. Because of its powerful antiproliferative
and anti-inflammatory effects, it has drawn a lot of attention from
researchers in the cancer field. To date, there are more than 70
clinical trials at various stages of completion, testing the efficacy of
curcumin against many diseases (www.clinicaltrials.gov). The role
of curcumin in modern medicine has been recently reviewed [26–
28]. The anticancer potential of curcumin is derived from its
ability to suppress proliferation of a wide variety of tumor cells, by
down-regulating the expression of proliferating genes such as
COX2, MMP-9, chemokines, cyclin D1 and the nuclear factor kB
(NF-kB) [29]. Tharakan et al., [30] using an orthotopic mouse
model of bladder cancer, reported that curcumin abolished the
constitutive activation of NF-kB in the tumor tissue, induced
apoptosis and decreased COX-2 expression. However, in the
presence of the chemotherapeutic drug, gemcitabine, low
concentrations of curcumin potentiates the effects of the drug
through the modulation of the NF-kB signaling pathway [31].
These observations clearly demonstrate the therapeutic potential
of curcumin in the treatment of cancer.
Since curcumin inhibits the proliferation of tumor cells by
targeting multiple sites in the apoptotic and proliferation
pathways, we hypothesized that superimposition of the multi-
targeted curcumin following molecular inhibition of Ki-67, would
have a greater inhibitory effect on tumor growth. Indeed, our data
show, for the first time, that pretreatment of bladder cancer cells
with DsiRNA against Ki-67 mRNA promotes cell-cycle arrest and
sensitizes the cells to curcumin-induced apoptosis. The putative
molecular targets of curcumin and Ki-67 DsiRNA are discussed.
Materials and Methods
SiRNA Design
A total of three DsiRNA duplexes targeted against rat Ki-67
mRNA were designed (Integrated DNA Technology, Coralville,
IA, USA). The sequences of the three DsiRNAs are as follows; 1)
Ki-67 -2; Sense sequence 59 – CGA ACA AAG UCA UCA GAC
ACA GUG A-39; antisense sequence 59- UCA CUG UGU CUG
AUG ACU UUG UUC GUU-39; 2) Ki-67-7; Sense sequence 59
– CAA GAG UGA GGG AGU GCC UUU GAA G-39; antisense
sequence 59 – CUU CAA AGG CAC UCC CUC ACU CUU
GUU -39 and 3) Ki-67-9; Sense sequence 59- CCA CCA GAG
CCA AUA GAU ACU UCA G-39 and antisense sequence 59-
CUG AAG UAU CUA UUG GCU CUG GUG GUG-39. An
irrelevant DsiRNA, hereafter referred as ‘control’ DsiRNA was
designed and has following sequence; Sense sequence 59- CAA
GAG UGA GGG AGU GCC UUU GAA G-39; antisense
sequence 59 – CUU CAA AGG CAC CGG AUC ACU CUU
GUU-39. Although the abbreviation ‘‘DsiRNA’’ is initially used to
emphasize the fact that the longer siRNAs were used in the current
study, the generic term ‘‘siRNA’’ is used interchangeably
throughout the text.
Cell Culture
Transplantable rat-derived TCC cells (AY-27 cells) were kindly
provided by Dr. Ronal Moore (University of Alberta, Canada).
The characterization of a bladder tumor model using this
transplantable cell line has been reported [32]. The cells were
maintained in monolayers, in a culture medium consisting of
RPMI-1640 (Gibco-BRL), supplemented with 10% FBS, 30 mM
HEPES (pH 7.3), 1 mM pyruvate, penicillin-streptomycin and
2.0 g/l of NaHCO3. Cells were maintained at 37uC in 5% CO2
and 95% air atmosphere by the method of Xiao et al [32]. AY-27
cells were passaged when confluent by standard trypsinization and
reculturing procedure. Where indicated, for comparative purpos-
es, human-derived T-24 bladder cancer cell lines (American Type
Culture Collection) were also used in this study and maintained in
tissue culture as described for AY-27 cells.
SiRNA Transfection
The day before transfection, cells were trypsinized, diluted with
fresh medium and transferred to 12-well plates (0.8–1.06105cells/
well). DsiRNAs were transfected using specifically designed
reagent for siRNA transfection (LipofectamineTM RNAiMax)
according to manufacturer’s protocol (Invitrogen, USA). Routine-
ly, transfection was carried out at 8–10% cell confluency.
Curcumin Treatment
When indicated, tumor cells were treated with various
concentrations of curcumin (Sigma-Aldrich, USA), either alone
or in combination with DsiRNA. Curcumin was dissolved in
DMSO, and in any given experiment, the final concentration of
DMSO was always less than 0.1% by volume.
Cellular Growth Curve
For evaluating tumor proliferation, tumor growth was assessed
by measuring the total number of cells at various stages. At each
stage, cells were detached by trypsinization, washed with PBS,
stained with trypan blue and the live cells were counted using a
hemocytometer. Each experimental condition was repeated three
to six times.
MTT Assay
The antiproliferative effects of siRNA against Ki-67 in the
presence or absence of curcumin was determined by the MTT
assay. The assay was based on the ability of mitochondria to
reduce 3-(4, 5 dimethylthiaol-2-yl)-2, 5-diphenyltetrazolium bro-
mide (MTT) dye in rat (AY-27) and human (T-24) bladder cancer
cells as detailed by Plumb [33]. Briefly, following exposure of the
cells to various treatment conditions, medium was removed, rinsed
with PBS, and MTT solution (5 mg/ml in RPMI medium) was
added and incubated for 37uC for 3 hours. Subsequently, the
medium was removed and replaced with an acid-isopropanol
solvent to dissolve the precipitate. The contents were placed on a
shaker for 5 mins and absorbance measured at 570 nm.
Quantitative Real-time PCR (qPCR)
After transfection with siRNAs and/or treatment with curcu-
min, cells were harvested at the appropriate interval and total
Ki-67 siRNA and Curcumin on Bladder Cancer Cells
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RNA was prepared by PureLink RNA mini kit (Invitrogen, USA).
For cDNA synthesis, 1 mg of total RNA was reverse transcribed to
cDNA in 20 ml reactions using Quantitect Reverse transcription
kit (Invitrogen, USA). qPCR was performed with the Light cyclerH
480 detection system (Roche, USA) using the BrilliantH SYBRH
Green QPCR Master mix protocol (Stratagene, USA). Briefly,
2 ml of cDNA was amplified by PCR in 25 ml reactions containing
12.5 ml of 26 SYBR green reagents and 0.2 mM of each of the
primers. The initial incubation for 10 min at 95uC was followed by
40 cycles at 95uC for 15 sec and 60uC for 1 min. Each experiment
was carried in triplicate.
Ki-67 Protein Expression: Immunofluorescence Staining
Cells were cultured on 25 mm glass coverslips in 6-well plates.
Following exposure to siRNA and/or curcumin under various
conditions, cells were washed with cold PBS and fixed with 4%
formaldehyde. After washing with PBS, the cells were incubated
with Ki-67 primary antibody (M19, Santa Cruz Biotechnology
Inc.,) (1:100) for 3 hours and washed thrice with PBS. The
coverslips were then incubated with FITC-labeled secondary
antibody (1:400) in the dark for an hour at room temperature,
washed with PBS and stained for 10 min with propidium iodide
(PI) solution. The coverslips were then washed with PBS and
mounted on a slide in the presence of mounting medium (Antifade
solution, Invitrogen, USA). The slides were then viewed under Bio
Rad Radiance 2001 system coupled to an Olympus IX70
microscope with 606 and 406 oil immersion objectives
(UAp0340, NA 1.35). A dual line Kr/Ar ion laser source was
used for imaging with excitation settings of 488 nm for FITC and
588 nm for PI.
Detection of Apoptosis by Annexin V Assay
Apoptosis was measured using PE Annexin V Apoptosis
Detection Kit I (BD Biosciences, USA) as per manufacturer’s
protocol. Briefly, following exposure to siRNA with or with out
curcumin, the cells were washed with cold PBS and then
resuspended in binding buffer followed by the addition of PE
Annexin V and 7-Amino-Acitomycin (7-AAD) and analyzed in
Beckman Coulter’s Epics XL-MCLTM Flow Cytometer, (USA).
Routinely, the average fluorescence derived from 20,000 cell
counts per sample was recorded.
Cell Cycle Analysis
To determine the effect of anti Ki-67 DsiRNA and/or
curcumin on the cell cycle phases, AY-27 cells were exposed to
various experimental conditions, the media removed and the cells
were detached by trypsinization. The cells were then washed with
PBS and fixed in ice-cold 70% ethanol for 2 hours at 220uC. The
cells were then washed once with PBS, resuspended in 300 ml of an
ice-cold modified PI solution (50 mg/ml PI solution, 0.1% Triton
X-100, and 0.1% sodium citrate, in PBS) and incubated for
30 min before analysis. PI fluorescence was measured by Beckman
Coulter’s Epics XL-MCLTM Flow Cytometer, (USA). Routinely,
the average fluorescence derived from 20,000 cell counts per
sample was recorded. Cells were scored as percentage of cells in
each of the cell cycle phases (Go/G1, S and G2/M).
Western Blot Analysis
Bladder cancer cells, after exposure to curcumin and DsiRNA
under various conditions, were trypsinized, washed with PBS, and
lysed with ice-cold RIPA (Sigma- Cat # R0278) buffer. The
lysates were kept on ice for 20 min, vortexed 3–4 times, and then
centrifuged in a microfuge at 12,000 rpm for 15 min at 0–4uC.
The supernatants were removed and assayed for protein content.
Aliquots (40 mg) of protein from each sample were dissolved in 46
NuPage lithium-dodecyl sulfate (LDS) and subjected to SDS-
PAGE under reducing conditions. The separated proteins were
transferred onto a nitrocellulose membrane and blocked in either
5% bovine serum albumin (BSA) or 5% non-fat dry milk in a Tris-
buffered saline containing 0.1% Tween-20 (TBST) by standard
procedures. The membranes were then incubated overnight at
4uC with the primary antibodies against following antigens: b-
actin, Cyclin E, and p53 (Santa Cruz Biotechnology, Inc., Santa
Cruz, CA, USA). Other antibodies used were against cleaved
Caspase3, phosphorylated-RB (pRb-P) (Cell Signaling Technolo-
gy, Inc, Danvers, MA ), Cyclin D1, (BD Bioscience, San Jose, CA),
Ki-67, NF-kB (p65 subunit), p27/Kip and p21 (Abcam, Cam-
bridge, MA). The blots were then washed extensively with TBS-T
and incubated with appropriate horseradish peroxidase-conjugat-
ed anti-mouse or anti-rabbit (Pierce Biotechnology/Thermo
Fisher Scientific, Rockford, IL) secondary antibodies at dilutions
1:15,000 and 1:20,000 respectively for 2 h at RT before the final
wash with TBST. The protein bands were detected by enhanced
chemiluminescence system using SuperSignal West Pico Chemi-
luminescent Substrate (Thermo Fisher Scientific, Rockford, IL).
The KODAK Image Station 440CF (Kodak Scientific Imaging
Systems, New Haven, CT) was used to visualize and quantify the
signal net intensity of bands. All experiments were performed in
triplicates. Representative blots are shown.
Protein Assay
Protein content in cell lysates were measured using Micro
BCATM protein assay kit (Pierce Biotechnology/Thermo Fisher
Scientific, Rockford, IL) using bovine serum albumin as the
internal standard.
Statistical Analysis
Where indicated, values are presented as mean 6 S.E of (n)
determinations. Data were subject to statistical analysis by paired
student’s t-test using the Microsoft Excel program and the values
with P,0.05 were considered to be statistically significant.
Results
Inhibition of Ki-67 Gene Expression and Cell Proliferation
by DsiRNA
The in vitro efficacies of three DsiRNA constructs targeted to rat
Ki-67 mRNA were tested as described above in AY-27 cells. As
shown in Figure 1A, out of the three DsiRNAs (Ki-67-2, -7, -9),
Ki-67-7 showed maximum inhibition. The mRNA expression,
analyzed by qPCR, showed a 39%, 50% and 28% decrease in the
expression of Ki-67 mRNA by Ki-67-2, Ki-67-7 and Ki-67-9
respectively when compared to cells treated with transfection
reagent alone. Similarly, cell viability assay by MTT showed that
Ki-67-7 treatment was the most effective of the three (Fig. 1B).
Thus, Ki-67-7 was chosen as the most effective DsiRNA against
Ki-67 mRNA for subsequent studies. Further, dose-response
studies showed that Ki-67-7 was most effective at 10 nM
concentration (1c). Under our experimental conditions, a further
increase in Ki-67-7 concentration did not enhance the anti-
proliferative effect of the siRNA.
Effect of Curcumin on Tumor Proliferation: Synergy with
Ki-67-7
The effects of curcumin and Ki-67-7 were tested in both
human-derived (T-24) and rat-derived (AY-27) bladder cancer
Ki-67 siRNA and Curcumin on Bladder Cancer Cells
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cells. Sequence comparisons showed that there was 80%
homology in the target sequence of Ki-67-7 between rat and
human Ki-67 mRNAs. In dose-response studies, we observed that
tumor cell growth was inhibited by curcumin in a dose-dependent
way (Figs. 2A and 2B) in both cell types but T-24 cells were more
sensitive to curcumin than AY-27 cells at 20 mM and above.
However, at 10 m M, the degree of inhibition (25–30%) was
similar in both cell types. In both cases, a drastic reduction (60–
85%) in cell viability was observed between 10 and 20 mM
curcumin. However, for purposes of comparing the combinatorial
effects of DsiRNA and curcumin (CusiRNA), the lower dose
(10 mM) of curcumin was used along with the optimal dose
(10 nM) of the DsiRNA (Ki-67-7). Data showed almost complete
(85%) inhibition of cell viability during the combined treatment of
curcumin and DsiRNA (Fig. 3A and 3B). Control siRNA had
insignificant effect on cell viability suggesting the specificity of Ki-
67-7 against its target.
The antiproliferative effect was also determined by monitoring
the cell growth curve. The growth curves based on cell numbers
were determined at 24, 48 and 72 hours after DsiRNA and
curcumin treatment. Combined treatment (CusiRNA) resulted in
a marked inhibition of cell proliferation and mimicked the same
trend as that of cell viability studies (Fig. 3C). The cellular
protein values also correlated well with growth curves (data not
shown).
Effects of Ki-67-7 and Curcumin on Ki-67 mRNA and
Protein Expression
To determine whether the reduction in tumor cell viability
during CusiRNA treatment was related to Ki-67 protein levels, we
measured the levels of both Ki-67 mRNA and protein expression.
Data show reductions in the levels of Ki-67 mRNA by 17%, 37%
and 57% when exposed to curcumin, Ki-67-7 and CusiRNA
respectively (Fig. 4A). Similarly, using immunofluorescence
staining technique, we observed that unlike Ki-67-7, curcumin
per se had minimal impact on Ki-67 protein expression (Fig. 4B).
Induction of Apoptosis by Ki-67-7 and Curcumin
Loss of cell viability is often the result of apoptosis or necrosis.
The extent of apoptosis, an early indicator of cell death, was
quantified by flow cytometric analysis using Annexin V to detect
the various stages of apoptosis (Fig. 5). Data suggest mild induction
of apoptosis when the cells were separately treated with curcumin
or Ki-67-7. However, the extent of apoptosis (the right two
quadrants in Fig. 5) in the presence of CusiRNA was found to be
synergistic (36% vs 13% for curcumin and 14% for Ki-67-7) after
correcting for baseline apoptosis (11%) in control cells (Fig. 5). The
figure also indicates (left top quadrant in Fig. 5) that the extent of
cell necrosis (Annexin V negative, 7AAD positive) was minimal
during all of the treatment conditions.
Ki-67-7 and Curcumin on Cell Cycle Phases
The effect of Ki-67-7 on cell cycle was determined in the
presence or absence of curcumin. Data show a general shift in the
direction of G0/G1 phase in all of the treatment conditions, but
the effect was maximal in the presence of CusiRNA (Fig. 6). There
was no significant change in G2/M phase when separately
exposed to either curcumin or Ki-67-7, but a 33% decrease was
observed when the cells were exposed to CusiRNA. Interestingly,
with an increase in G0/G1 and decrease in G2/M phases, there
Figure 1. Effect of various DsiRNA constructs on a) Ki-67 mRNA expression and b) cell proliferation in bladder cancer cells; c) Dose-
response studies with Ki-67-7. a) Rat TCC cells (AY-27) were cultured in 12-well plates (,0.86105 cells/well) as described in
Materials and Methods. After 24 h, they were transfected with each of the siRNA constructs (Ki-67-2, Ki-67-7 and Ki-67-9) targeted against Ki-67
mRNA. After 48 h, RNA was extracted and the levels of mRNA were determined by quantitative PCR as described in Methods. Cells treated with the
transfection reagent alone were used as the control. The rate of expression of Ki-67 mRNA was normalized to the expression of b-actin. Values
represent data from one (of two) experiment using the average of triplicate determinations. b) AY-27 cells were cultured in 12-well (0.86105 cells/
well) plates for 24 h and transfected with various siRNA constructs as described in Methods. Cell viability was determined 48 h after transfection by
MTT assay. Cells treated with transfection reagent alone served as the control ( = 100%). Bars indicate values which are the means 6 S.E of three
determinations. (*P,0.05). c) AY-27 cells were cultured in 12-well plates (0.86105 cells/well) as described in Methods. Forty eight hours after siRNA
transfection, the effect of various concentrations of Ki-67-7 on cell viability was determined by MTT assay. Cells treated with transfection reagent
alone served as the control. Cell viability values are expressed as percent control and are the means 6 S.E of 3-8 determinations (*P,0.05,
***P,0.005).
doi:10.1371/journal.pone.0048567.g001
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was a two-fold shift (ratio of G0/G1 to G2/M) towards growth
arrest in the presence of CusiRNA compared to control
(Fig. 6).
Effect of Ki-67-7 and Curcumin on Multiple Signaling:
Molecular Targets in Cell Cycle And Apoptosis
Inhibition of cell cycle progression, induction of apoptosis or a
combination of both, are the key events associated with tumor
Figure 2. Dose-dependent effects of curcumin on bladder cancer cell proliferation. T-24 (2a) and AY-27 (2b) cells were plated in 12-well
plates (0.86105 cells/well) and cultured for 48 hr (40–50% confluence) as described in Methods. Following exposure to various concentrations of
curcumin for 24 h, cells were washed with PBS and incubated for another 24 h in curcumin-free medium. Cells incubated with DMSO (0.1%) alone
were treated as controls. DMSO alone had little impact on tumor cell growth (data not shown). Cell proliferation was assessed on the basis of cell
viability, measured by MTT assay. Cell viability was expressed as percent of viability observed in DMSO-treated control cells. Values are from a
representative (of two) (2a) or 3–8 (mean 6 S.E) determinations (2b). *P,0.05, **P,0.01, ***P,0.005.
doi:10.1371/journal.pone.0048567.g002
Figure 3. Effect of the combined treatment of anti-Ki-67 DsiRNA and curcumin on bladder cancer cells. Equal number (0.86105 cells/
well) of bladder cancer cells T-24 (3a) and AY-27 (3b) cultured as described in Methods were either transfected with Ki-67–7 or control DsiRNA
(10 nM) or treated with the transfection reagent alone for 24 h. Subsequently, where indicated, curcumin (10 mM) was added to the cells and
incubated for 24 h followed by an additional 24 h incubation in the absence of curcumin. Cell viability was determined by MTT assay at the end of
72 h from transfection. Cells treated with DMSO plus transfection reagent served as the control. Data presented are the mean 6 S.E of 3–5
determinations (*P,0.05, **P,0.01). 3c) AY-27 cells (0.86105 cells/well) were treated exactly as described above in legend to Figures 3A and 3B and
at the end of 24, 48 and 72 h after curcumin treatment (which is same as 48, 72 and 96 h after siRNA transfection), cell growth was assessed based on
cell numbers as described in Methods. Data are mean 6 S.E of three determinations.
doi:10.1371/journal.pone.0048567.g003
Ki-67 siRNA and Curcumin on Bladder Cancer Cells
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inhibition. Data presented above clearly suggest that a combina-
tion of curcumin and Ki-67-7 affect both the events. In order to
understand the role of some of molecular intermediates that are
likely to affect these events, we determined the levels of some of the
regulatory proteins associated with apoptosis and cell cycle
progression. Increased levels of cleaved-caspase3 by Western blot
analysis confirmed the induction of apoptosis, which was most
pronounced in the CusiRNA group (Fig. 7). However, there was a
marked reduction in the levels of the tumor suppressor protein,
p53, in the same group. Cyclins D1 and E, the proteins associated
with G1-S transition in the cell cycle phases, were also profoundly
inhibited by CusiRNA. As expected, reduction in cyclin D1 was
associated with a reduction in the levels of pRb-P. Reduction in
p53 was also associated with a reduction in p21, an inhibitor of
cyclin E. However, it was the increase in p27 protein, another
inhibitor of cyclin E that seemed to correlate well with the
inhibition of cyclin E in the CusiRNA group. These observations
were similar in both cell types. On the other hand, the inhibition of
the transcription factor NF-kB was more attributable to curcumin
treatment in AY-27 cells whereas in T-24 cells, it was inhibited
primarily by CusiRNA.
Discussion
Transitional cell carcinoma (TCC) of the urinary bladder is the
most common cancer in the urinary system. Although the
incidence of urinary bladder cancer has continuously increased
during the past three decades, there has been little progress in its
treatment. Following TUR, tumor recurrence and drug-related
toxic side-effects are some of the challenges facing the treatment of
bladder cancer. Therefore, the objective of our study was to test a
novel approach that was intended to cause significant inhibition of
tumor growth with minimal toxicity.
Ki-67 antigen, although often used as a proliferation marker
because of its high transcription rate, is beginning to be used as a
target in the treatment of various types of cancer [16–21]. The role
of curcumin in suppressing the pathways linked to oncogenesis,
including cell survival, proliferation, invasion and angiogenesis has
already been discussed. Effects on multiple sites such as protein
kinase C activation, the alteration of transcriptional factors such
as, c-jun/AP-2, NF-kB and p53 by curcumin have been reported
[34]. However, our studies were aimed at using curcumin as a co-
drug since it is now well-established that curcumin can indeed
potentiate the effects of anticancer drugs [30]. Therefore, the aim
of the present study was to evaluate whether we could demonstrate
a synergy between the multi-targeted curcumin and Ki-67-7, the
anti-Ki-67 siRNA.
In cell culture studies, it was possible to achieve greater than
50% inhibition of tumor cell growth at 20 mM concentration of
curcumin. However, we routinely used a sub-maximal dose of
10 mM, to specifically study the combined interaction of curcumin
and anti-Ki-67 siRNA. Our data show that although 10 nM of Ki-
67-7 significantly inhibited cell proliferation, almost a total
inhibition of bladder cancer cell growth was achieved in the
Figure 4. Effect of Ki-67-7 and curcumin on Ki-67 a) gene and b) protein expression in bladder cancer cells. a) AY-27 cells were treated
with Ki-67 siRNA in the presence or absence of curcumin exactly as described in legend to Figures 3A and 3B. At the end of the treatment, RNA was
extracted and Ki-67 mRNA expression was determined by quantitative PCR using b-actin as the internal standard as described in Methods. Ki-67
mRNA levels are expressed as percent of the rate of expression in control cells which were treated with transfection reagent and DMSO. Bars indicate
values which are the mean6 S.E of three determinations. b) AY-27 cells were grown on glass coverslips placed inside 12-well plates and treated with
siRNA (Ki-67-7), curcumin or as a combination, as described in the legend to Figures 3A and 3B. At the end of the treatment period, cells were
exposed to Ki67 primary antibody (M19) and FITC-labeled secondary antibody followed by PI (Propidium iodide), and observed under confocal
microscopy as described in Methods. Scale bar inserts = 5 mm. Increased down-regulation of Ki-67 protein due to Ki-67-7 was observed.
doi:10.1371/journal.pone.0048567.g004
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combined presence of curcumin (10 mM) (Fig. 3). The advantage
of using low concentrations of two separate classes of drugs can be
appreciated when we compare our data with those of Zheng et al
[19], in which, they had to use a ten-fold higher concentration
(100 nM) of anti-Ki-67 siRNA to inhibit tumor proliferation only
by 45%. Additionally, with regard to curcumin, a lower dose is
preferable since increasing its concentration (.50 mM) is also
known to be toxic to non-tumor cells [35].
In the current study, we also attempted to correlate the
antiproliferative properties of curcumin and Ki-67-7 on various
cellular processes such as apoptosis, cell-cycle progression and Ki-
67 expression. Our data show that although curcumin and Ki-67-
7 both showed similar degrees of inhibitory effect on cell viability,
addition of curcumin to Ki-67-7-treated cells almost completely
inhibited cell proliferation with minimal impact on Ki-67
expression (compare Figs. 3B and 4). This suggested that although
curcumin per se had minimal impact on Ki-67, when Ki-67
expression is suppressed by the siRNA, curcumin-mediated
processes operate cooperatively to enhance apoptotic cell death
in tumor cells. Thus, our data demonstrate for the first time, a
synergy between a low concentration of curcumin and an anti-Ki-
67 siRNA (Ki-67-7) in the inhibition of bladder cancer cells. The
possible molecular targets of the CusiRNA are discussed below.
The initial testing of the interaction between curcumin and Ki-
67-7 against bladder cancer cells was measured by MTT assay.
Although MTT assay, which determines cell viability, provides the
end result, it does not provide information on the events, such as
cell cycle arrest and apoptosis that lead to tumor inhibition. An
early indicator of apoptosis is the rapid translocation of
phosphatidyl serine from the cytoplasmic side of the plasma
membrane to the extracellular surface. The loss of asymmetry can
be detected by using the binding properties of Annexin V to cell
Figure 5. Determination of Ki-67-7 and curcumin-induced apoptosis by flow cytometry. AY-27 cells were treated with anti-Ki-67 siRNA,
curcumin or in the combined presence of both as described in legend to Figures 3A and 3B. At the end of the treatment period, the cells were
harvested, stained with fluorescence-conjugated Annexin V and 7AAD as described in Methods. Following flow cytometric analysis, the percentage
(number inserts in the figure) of normal cells or those undergoing apoptosis and necrosis was calculated using appropriate software (Flow Jo v.9). The
rate of apoptosis was measured by adding the percentages in the right two quadrants in each of the figures. The data are from a representative (of
two identical) experiment.
doi:10.1371/journal.pone.0048567.g005
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surface. In the present study, a sensitive assay of apoptosis by flow
cytometry using Annexin V, clearly demonstrated the synergy
between Ki-67-7 and curcumin during the early stages of apoptosis
(Fig. 5). Such an observation is reminiscent of the synergy between
curcumin and the chemotherapeutic drugs, such as gemcitabine
[31] and paclitaxel [36], except that siRNAs are far less toxic
compared to those drugs.
During cell proliferation, the key cell-cycle events involve
transition from one phase to the next; resting (G0), increase in
cellular contents (G1), DNA replication (S), chromosome check
point and preparation for mitosis (G2) and mitosis (M). Since Ki-
67 antigen is involved in DNA replication, an inhibition of this
protein was expected to affect the cell cycle phases, specifically at
the S phase. As expected, there was a 40% reduction in the
number of cells in the S phase when treated with Ki-67-7 and
marginal reduction by curcumin. However, in the presence of
CusiRNA, a major shift towards growth arrest was observed as
indicated by a 2-fold increase in the ratio of G0/G1 to G2/M
compared to other treatment groups (Fig. 6). Such a drastic shift in
cell cycle phases, in favor of growth arrest and against mitosis (G2/
M), was associated with an almost total inhibition of tumor cells
(Fig. 3). Kausch et al [17] have suggested that in the absence of Ki-
67, cells that attempt mitosis may be forced into apoptosis.
However, our data suggest that the apoptotic process was
minimally affected by the inhibition of Ki-67 (caspase-3, Fig. 7)
but profoundly enhanced by the addition of curcumin (Fig. 5).
Although a detailed analysis of the molecular mechanisms
underlying the inhibition of tumor cell growth by curcumin and
Ki-67-7 is beyond the scope of this study, our data show the
following (see Fig. 8 for the scheme): Cyclins D1 and E were both
inhibited by CusiRNA, thus affecting the cell cycle progression.
Reduction in cyclin D1 was also associated with lower pRb-P
levels, a downstream activator molecule regulated by cyclin D1.
Further, an increase in the level of p27 by CusiRNA, an inhibitor
of cyclin E also favored growth arrest. However, the most striking
observation of this study is the profound inhibition of both p53 and
p21 proteins by CusiRNA (Fig. 7). These two proteins are
generally activated by curcumin treatment [37]. In an earlier
study, Tian et al [38] reported that exposure of T-24 cells to
curcumin resulted in an increased expression of p53 along with the
induction of apoptotic cell death and cell cycle arrest in the G2/M
phase. However, unlike in our studies, they had to use a much
higher dose (40 mM) of curcumin since the inhibition of tumor
growth was low at 10 mM. Since p21 is regulated by p53 [39], the
inhibition of p53 may explain the absence of p21, another
Figure 6. Effect of Ki-67-7 and curcumin on cell cycle phases.
AY-27 cells were treated with Ki-67-7, curcumin or with both, as
described earlier in legend to Figures 3A and 3B. At the end of the
incubation period, the cells were treated with PI and the distribution of
cells in various cell cycle phases were determined by flow cytometry as
described in Methods. Cells were scored as percentage distribution of
cells in each of the cell cycle phases (Go/G1, S and G2/M). Bars indicate
values which are the means 6 S.E of three determinations.
doi:10.1371/journal.pone.0048567.g006
Figure 7. Effect of Ki-67-7 and curcumin on the regulatory
proteins of cell cycle phases and apoptosis: Western blot
analysis. Bladder cancer cells (T-24 and AY-27) were cultured and
exposed to Ki-67-7 and curcumin as described above in legend to
Figures 3A and 3B. At the end of the treatment period, total protein
was extracted and subjected to Western blotting using appropriate
antibodies as described in Methods. For purposes of associating
proteins with specific roles, they were grouped in separate categories,
such as gene transcription (A), cell-cycle progression (B) and apoptosis
(C). b-actin was used as the internal control. Since different pro-
teins (e.g. Cyclin D1 and NF-kB) from the same membrane were
identified in separate categories, the same b-actin blot is displayed
on more than one occasion. Data presented are western blots from
a single experiment, which is representative of 2–3 identical
experiments.
doi:10.1371/journal.pone.0048567.g007
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regulator of cyclin E. Nevertheless, the possibility for tumor cells to
undergo apoptosis in the absence of p53 and p21, but in the
presence of chemotherapeutic drugs has also been reported [40].
Taken together, our data suggest that in bladder cancer cells, prior
exposure to anti-Ki-67 siRNA, predisposes the tumor cells to
curcumin-induced growth arrest and apoptosis by non-p53 and
non-p21-dependent pathways.
Conclusions
In summary, our studies show, for the first time, that anti-Ki-67
siRNA, in the combined presence of a low concentration of
curcumin, was highly effective against the proliferation of bladder
cancer cells. Future studies are required to identify the molecular
mechanisms that are involved in the prevention of tumor growth
during the combined treatment with anti-Ki-67 siRNA and
curcumin. The outcome of our studies could form a new basis for a
non-toxic treatment of bladder cancer patients who undergo
TUR.
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